收费全文 | 1437篇 |
免费 | 88篇 |
国内免费 | 6篇 |
耳鼻咽喉 | 18篇 |
儿科学 | 40篇 |
妇产科学 | 81篇 |
基础医学 | 210篇 |
口腔科学 | 47篇 |
临床医学 | 251篇 |
内科学 | 223篇 |
皮肤病学 | 56篇 |
神经病学 | 107篇 |
特种医学 | 30篇 |
外科学 | 91篇 |
综合类 | 8篇 |
一般理论 | 2篇 |
预防医学 | 186篇 |
眼科学 | 13篇 |
药学 | 75篇 |
中国医学 | 19篇 |
肿瘤学 | 74篇 |
2024年 | 2篇 |
2023年 | 11篇 |
2022年 | 12篇 |
2021年 | 34篇 |
2020年 | 15篇 |
2019年 | 34篇 |
2018年 | 27篇 |
2017年 | 44篇 |
2016年 | 33篇 |
2015年 | 43篇 |
2014年 | 51篇 |
2013年 | 112篇 |
2012年 | 142篇 |
2011年 | 108篇 |
2010年 | 74篇 |
2009年 | 51篇 |
2008年 | 94篇 |
2007年 | 81篇 |
2006年 | 92篇 |
2005年 | 90篇 |
2004年 | 83篇 |
2003年 | 63篇 |
2002年 | 62篇 |
2001年 | 14篇 |
2000年 | 6篇 |
1999年 | 11篇 |
1998年 | 20篇 |
1997年 | 8篇 |
1996年 | 9篇 |
1995年 | 17篇 |
1994年 | 6篇 |
1993年 | 8篇 |
1992年 | 7篇 |
1991年 | 4篇 |
1990年 | 4篇 |
1989年 | 4篇 |
1988年 | 8篇 |
1987年 | 2篇 |
1986年 | 4篇 |
1985年 | 4篇 |
1984年 | 3篇 |
1983年 | 2篇 |
1982年 | 3篇 |
1981年 | 6篇 |
1980年 | 4篇 |
1979年 | 10篇 |
1978年 | 4篇 |
1975年 | 1篇 |
1971年 | 1篇 |
1969年 | 1篇 |
Background
Progressive encephalopathy (PE) in children is a heterogeneous group of diseases mainly composed of metabolic diseases, but it consists also of neurodegenerative disorders where neither metabolic nor other causes are found. We wanted to estimate the incidence rate and aetiology of PE, as well as the age of onset of the disease. 相似文献Aims
Dabigatran is largely cleared by renal excretion. Renal function is thus a major determinant of trough dabigatran concentrations, which correlate with the risk of thromboembolic and haemorrhagic outcomes. Current dabigatran dosing guidelines use the Cockcroft–Gault (CG) equation to gauge renal function, instead of contemporary equations including the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations employing creatinine (CKD-EPI_Cr), cystatin C (CKD-EPI_Cys) and both renal biomarkers (CKD-EPI_CrCys).Methods
A linear regression model including the dabigatran etexilate maintenance dose rate, relevant interacting drugs and genetic polymorphisms (including CES1), was used to analyse the relationship between the values from each renal function equation and trough steady-state plasma dabigatran concentrations.Results
The median dose-corrected trough steady-state plasma dabigatran concentration in 52 patients (38–94 years) taking dabigatran etexilate was 60 µg/L (range 9–279). The dose-corrected trough concentration in a patient on phenytoin and phenobarbitone was >3 standard deviations below the cohort mean. The CG, CKD-EPI_Cr, CKD-EPI_Cys and CKD-EPI_CrCys equations explained (R2, 95 % CI) 32 % (9–55), 37 % (12–60), 41 % (16–64) and 47 % (20–69) of the variability in dabigatran concentrations between patients, respectively. One-way analysis of variance (ANOVA) comparing the R2 values for each equation was not statistically significant (p = 0.74).Discussion
Estimates of renal function using the four equations accounted for 32–47 % of the variability in dabigatran concentrations between patients. We are the first to provide evidence that co-administration of phenytoin/phenobarbitone with dabigatran etexilate is associated with significantly reduced dabigatran exposure.Electronic supplementary material
The online version of this article (doi:10.1007/s40268-014-0045-9) contains supplementary material, which is available to authorized users. 相似文献Objectives
The aims were to study biomarkers of systemic inflammation, platelet/endothelial activation and thrombosis in tunnel construction workers (TCW).Methods
Biomarkers and blood fatty acids were measured in blood of 90 TCW and 50 referents before (baseline) and towards the end (follow-up) of a 12 days work period. They had been absent from work for 9 days at baseline. Air samples were collected by personal sampling.Results
Personal thoracic air samples showed geometric mean (GM) particulate matter and α-quartz concentrations of 604 and 74 µg/m3, respectively. The arithmetic mean (AM) concentration of elemental carbon was 51 µg/m3. The GM (and 95% confidence interval) concentration of the pro-inflammatory cytokine TNF-α decreased from 2.2 (2.0–2.4) at baseline to 2.0 pg/mL (1.8–2.2) (p?=?0.02) at follow-up among the TCW. Also the platelet activation biomarkers P-selectin and CD40L decreased significantly [25.4 (24.1–26.6) to 24.4 (22.9–26.0)] ng/mL, p?=?0.04 and 125 (114–137) to 105 (96–115) pg/mL, p?<?0.001, respectively. ICAM-1 concentrations increased from 249 (238–260) to 254 (243–266) ng/mL (p?=?0.02). No significant alterations were observed among the referents when assessed by paired sample t test. Unbeneficial alterations in blood fatty acid composition were observed between baseline and follow-up, mainly among referents.Conclusions
TCW had slightly reduced systemic inflammation and platelet activation although highly exposed to particulate matter, α-quarz and diesel exhaust, which might be due to increased physical activity during the exposure period. The slightly increased ICAM-1 may indicate monocyte recruitment to the lungs. The diet was substantially altered towards a less beneficial fatty acid profile.Several studies in Europe and the US have shown promising results favouring digital breast tomosynthesis compared to standard digital mammography (DM). However, the costs of implementing the technology in screening programmes are not yet known.
MethodsA randomised controlled trial comparing the results from digital breast tomosynthesis including synthetic mammograms (DBT) vs. DM was performed in Bergen during 2016 and 2017 as a part of BreastScreen Norway. The trial included 29,453 women and allowed for a detailed comparison of procedure use and screening, recall and treatment costs estimated at the individual level.
ResultsThe increased cost of equipment, examination and reading time with DBT vs. DM was €8.5 per screened woman (95% CI 8.4−8.6). Costs of DBT remained significantly higher after adding recall assessment costs, €6.2 (95% CI 4.6−7.9). Substantial reductions in either examination and reading times, price of DBT equipment or price of IT storage and connectivity did not change the conclusion. Adding treatment costs resulted in too wide confidence intervals to draw definitive conclusions (additional costs of tomosynthesis €9.8, 95% CI –56 to 74). Performing biopsy at recall, radiation therapy and chemotherapy was significantly more frequent among women screened with DBT.
ConclusionThe results showed lower incremental costs of DBT vs. DM, compared to what is found in previous cost analyses of DBT and DM. However, the incremental costs were still higher for DBT compared with DM after including recall costs. Further studies with long-term treatment data are needed to understand the complete costs of implementing DBT in screening.
相似文献